Camp4 Therapeutics outlines Phase 1/2 ASCEND trial plan for CMP-002, first patient dosing by end of 2026

Camp4 Therapeutics announced design and timelines for its Phase 1/2 ASCEND trial of CMP-002, targeting first patient dosing by end of 2026.Key Highlights:Original SEC Filing: Camp4 Therapeutics Corp [ CAMP ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider v…